S3 Fig -

Forest plot for subgroup analysis of CR(A), PR(B), ORR(C) and DCR(D) based on RCT/Non-RCT. (DOCX)</p

Fig 13 -

Begg’s funnel plot (A) and sensitivity analysis (B) of PR. Begg’s test (P = 0.692).</p

Characteristics of studies included.

ObjectivesTo compare the clinical curative effects, survival and complications of recombinant human adenovirus-p53 (rAd-p53) combined with transcatheter arterial chemoembolization (TACE) versus TACE for the treatment of liver cancer.MethodsWe searched all the eligible studies of rAd-p53 plus TACE versus control group had only TACE in the treatment of liver cancer, which were retrieved from CNKI, Wanfang database, CBM, VIP, PubMed, EMBase, The Chrance of Library, Web of Science from its inception to august 2022.ResultsA total of 17 studies were included, which involved 1045 patients. The results of the meta analysis indicated that the the rAd-p53combined with TACE markedly improved the patients’ complete remission(OR = 2.19, 95% CI:1.13–4.22, P = 0.02), partial remission (OR = 2.22, 95% CI:1.67–2.94, PConclusionRAd-p53 combined with TACE for liver cancer showed significant advantages in terms of clinical efficacy, survival rate, and safety compared to the TACE alone, and effectively improved patient quality of life and immune function.Systematic review registrationhttps://inplasy.com/inplasy-2022-9-0127/.</div

Fig 14 -

Begg’s funnel plot (A) and sensitivity analysis (B) of ORR.Begg’s test (P = 0.005).</p

Fig 7 -

Forest plot for six-month (A), one-year (B), and two-year (C) survival rates of rAd-p53 combined with TACE group and TACE alone group.</p

Forest plot for AFP change of rAd-p53 combined with TACE group and TACE alone group.

Forest plot for AFP change of rAd-p53 combined with TACE group and TACE alone group.</p

Forest plot for DCR of rAd-p53 combined with TACE group and TACE alone group.

Forest plot for DCR of rAd-p53 combined with TACE group and TACE alone group.</p

Flow chart of studies screening.

ObjectivesTo compare the clinical curative effects, survival and complications of recombinant human adenovirus-p53 (rAd-p53) combined with transcatheter arterial chemoembolization (TACE) versus TACE for the treatment of liver cancer.MethodsWe searched all the eligible studies of rAd-p53 plus TACE versus control group had only TACE in the treatment of liver cancer, which were retrieved from CNKI, Wanfang database, CBM, VIP, PubMed, EMBase, The Chrance of Library, Web of Science from its inception to august 2022.ResultsA total of 17 studies were included, which involved 1045 patients. The results of the meta analysis indicated that the the rAd-p53combined with TACE markedly improved the patients’ complete remission(OR = 2.19, 95% CI:1.13–4.22, P = 0.02), partial remission (OR = 2.22, 95% CI:1.67–2.94, PConclusionRAd-p53 combined with TACE for liver cancer showed significant advantages in terms of clinical efficacy, survival rate, and safety compared to the TACE alone, and effectively improved patient quality of life and immune function.Systematic review registrationhttps://inplasy.com/inplasy-2022-9-0127/.</div

Pubmed literature search strategies.

ObjectivesTo compare the clinical curative effects, survival and complications of recombinant human adenovirus-p53 (rAd-p53) combined with transcatheter arterial chemoembolization (TACE) versus TACE for the treatment of liver cancer.MethodsWe searched all the eligible studies of rAd-p53 plus TACE versus control group had only TACE in the treatment of liver cancer, which were retrieved from CNKI, Wanfang database, CBM, VIP, PubMed, EMBase, The Chrance of Library, Web of Science from its inception to august 2022.ResultsA total of 17 studies were included, which involved 1045 patients. The results of the meta analysis indicated that the the rAd-p53combined with TACE markedly improved the patients’ complete remission(OR = 2.19, 95% CI:1.13–4.22, P = 0.02), partial remission (OR = 2.22, 95% CI:1.67–2.94, PConclusionRAd-p53 combined with TACE for liver cancer showed significant advantages in terms of clinical efficacy, survival rate, and safety compared to the TACE alone, and effectively improved patient quality of life and immune function.Systematic review registrationhttps://inplasy.com/inplasy-2022-9-0127/.</div

Forest plot for adverse reactions of rAd-p53 combined with TACE group and TACE alone group.

Forest plot for adverse reactions of rAd-p53 combined with TACE group and TACE alone group.</p